Literature DB >> 15081003

Novel CCR1 antagonists with improved metabolic stability.

Matthew F Brown1, Mike Avery, William H Brissette, J H Chang, Kevin Colizza, Maryrose Conklyn, Amy P DiRico, Ronald P Gladue, John C Kath, Suzanne S Krueger, Paul D Lira, Brett M Lillie, Greg D Lundquist, Erin N Mairs, Eric B McElroy, Molly A McGlynn, Timothy J Paradis, Christopher S Poss, Michelle I Rossulek, Richard M Shepard, Jeff Sims, Timothy J Strelevitz, Susan Truesdell, Laurie A Tylaska, Kwansik Yoon, Deye Zheng.   

Abstract

The synthesis, biological activity, and pharmacokinetic profile of novel CCR1 antagonists are described.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081003     DOI: 10.1016/j.bmcl.2004.02.022

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Phosphoproteomic characterization of the signaling network resulting from activation of the chemokine receptor CCR2.

Authors:  Cheng Huang; Simon R Foster; Anup D Shah; Oded Kleifeld; Meritxell Canals; Ralf B Schittenhelm; Martin J Stone
Journal:  J Biol Chem       Date:  2020-04-02       Impact factor: 5.157

Review 2.  CCR1 antagonists.

Authors:  Jie-Fei Cheng; Rick Jack
Journal:  Mol Divers       Date:  2008-06-17       Impact factor: 2.943

3.  2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and Mycobacterium tuberculosis: Structure-Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization.

Authors:  Dinakaran Murugesan; Peter C Ray; Tracy Bayliss; Gareth A Prosser; Justin R Harrison; Kirsteen Green; Candice Soares de Melo; Tzu-Shean Feng; Leslie J Street; Kelly Chibale; Digby F Warner; Valerie Mizrahi; Ola Epemolu; Paul Scullion; Lucy Ellis; Jennifer Riley; Yoko Shishikura; Liam Ferguson; Maria Osuna-Cabello; Kevin D Read; Simon R Green; Dirk A Lamprecht; Peter M Finin; Adrie J C Steyn; Thomas R Ioerger; Jim Sacchettini; Kyu Y Rhee; Kriti Arora; Clifton E Barry; Paul G Wyatt; Helena I M Boshoff
Journal:  ACS Infect Dis       Date:  2018-03-26       Impact factor: 5.084

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.